tazobactam has been researched along with Pseudomonas Infections in 196 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.51) | 18.2507 |
| 2000's | 15 (7.65) | 29.6817 |
| 2010's | 91 (46.43) | 24.3611 |
| 2020's | 89 (45.41) | 2.80 |
| Authors | Studies |
|---|---|
| Bonnet, R; Casin, I; Doublet, B; Fabre, L; Le Fleche, A; Robin, F; Weill, FX | 1 |
| De Luca, F; Docquier, JD; Ide, L; Nordmann, P; Poirel, L; Rossolini, GM; Verlinde, A | 1 |
| Kotsakis, SD; Legakis, NJ; Miriagou, V; Papagiannitsis, CC; Tzelepi, E; Tzouvelekis, LS | 1 |
| Barraja, P; Carbone, A; Cascioferro, S; Cirrincione, G; Diana, P; Montalbano, A; Parrino, B; Schillaci, D; Spanò, V | 1 |
| Bremmer, DN; Kline, EG; Nicolau, DP; Shah, S; Shields, RK | 1 |
| DePestel, DD; DeRyke, CA; Garrison, MW; Harris, KA; Moise, PA; Pfaller, MA; Sader, HS; Shortridge, D | 1 |
| Horcajada, JP; López Montesinos, I; Montero, M; Sorlí, L | 1 |
| Carvalhaes, CG; Castanheira, M; Sader, HS; Shortridge, D | 1 |
| Castanheira, M; Duncan, LR; Mendes, RE; Sader, HS | 1 |
| Angulo-Brunet, A; Campillo, N; Domene-Ochoa, S; Ferrer-Alapont, L; Grau, S; Horcajada, JP; López-Causapé, C; Luque, S; Montero, MM; Oliver, A; Padilla, E; Prim, N; Sorlí, L | 1 |
| Alcalde-Rico, M; Arias, CA; García, P; Khan, A; Martínez, JRW; Miller, WR; Moreno, MV; Munita, JM; Olivares-Pacheco, J; Rivas, L; Rojas, P; Wozniak, A | 1 |
| Chen, WT; DeRyke, CA; Kazmierczak, KM; Lob, SH; Motyl, MR; Sahm, DF; Siddiqui, F; Young, K | 1 |
| Alonso-García, I; Arca-Suárez, J; Beceiro, A; Bou, G; Fernández-Pérez, B; Fraile-Ribot, PA; Gato, E; González-Bello, C; Guijarro-Sánchez, P; Gutiérrez-Urbón, JM; Lasarte-Monterrubio, C; Oliver, A; Oviaño, M; Ruedas-López, A; Vallejo, JA; Vázquez-Ucha, JC; Velasco, D | 1 |
| Cabot, G; Gomis-Font, MA; Juan, C; López-Argüello, S; Moyá, B; Oliver, A; Zamorano, L | 1 |
| Al Musawa, M; Alattas, M; Alfahad, W; Alfozan, A; Alghamdi, A; Alhameed, AF; Aljabri, A; Almangour, TA; Almohaizeie, A; Almuhisen, S; Alraddadi, BM; AlShahrani, FS; Binkhamis, KM; Damfu, N; Khuwaja, M; Qutub, M | 1 |
| Al-Alawi, MM; Ali, HE; Almutairi, AF; AlTurki, R; Bahabri, NM; Janah, SS; Khalil, S; Qutub, MO; Tashkandi, WA | 1 |
| Carratalà, J; Cuervo, G; González Laguna, M; Llop Talaveron, J; Padullés, A; Pérez-Recio, S; Ronda, M; Soldevila-Boixader, L; Tubau Quintano, MF | 1 |
| Csékó, AB; Gál, J; Hermann, C; Iványi, ZD; Mogyoródi, B | 1 |
| Chew, KL; Leong, Q | 1 |
| Alcaraz-Serrano, V; Amaro, R; Bueno-Freire, L; Cabrera, R; Fernández-Barat, L; López-Aladid, R; Muñoz, L; Oscanoa, P; Torres, A; Vázquez, N; Vila, J | 1 |
| Candel, FJ; González Del Castillo, J; Julián Jiménez, A; Matesanz, M | 1 |
| DeRyke, CA; Hilbert, DW; Karlowsky, JA; Lob, SH; Motyl, MR; Sahm, DF; Siddiqui, F; Wong, MT; Young, K | 1 |
| Benítez-Cano, A; Grau, S; Luque, S; Navarrete-Rouco, ME; Roberts, JA; Sorlí, L | 1 |
| Antonelli, A; Brenciani, A; Brescini, L; Castelletti, S; Cirioni, O; D'Achille, G; Di Pilato, V; Fioriti, S; Giacometti, A; Giani, T; Giovanetti, E; Masucci, A; Mingoia, M; Morroni, G; Rossolini, GM | 1 |
| Alonso-García, I; Arca-Suárez, J; Beceiro, A; Bou, G; Cabot, G; Fraile-Ribot, PA; Galán-Sánchez, F; Guijarro-Sánchez, P; Lasarte-Monterrubio, C; Oliver, A; Rumbo-Feal, S; Vázquez-Ucha, JC | 1 |
| Castanheira, M; Collingsworth, TD; DeVries, S; Doyle, TB; Hubler, CM; Mendes, RE | 1 |
| Abbara, D; Afaneh, L; Al Duhailib, Z; Al Qahtani, MM; Al Sulaiman, K; Aldhayyan, N; Askar, G; Dyab, N; Hakeam, HA; Islami, M; Mansour, R | 1 |
| Bachta, KER; Bertucci, HK; Brunzelle, JS; Gatesy, SWM; Hauser, AR; Lebrun-Corbin, M; Minasov, G; Ozer, EA; Pincus, NB; Rosas-Lemus, M; Satchell, KJF; Shuvalova, LA | 1 |
| Haines, RR; Hammer, KA; Putsathit, P; Tai, AS | 1 |
| Alekseeva, I; DeRyke, CA; Estabrook, MA; Lob, SH; Motyl, MR; Sahm, DF; Siddiqui, F; Young, K | 1 |
| Guery, B; Jacot, D; Papadimitriou-Olivgeris, M | 1 |
| Baretta, V; Calore, E; Carraro, F; Cesaro, S; Colombini, A; Meazza, C; Muggeo, P; Onofrillo, D; Perruccio, K; Rosaria D'Amico, M; Zama, D | 1 |
| Gill, CM; Nicolau, DP | 1 |
| Alekseeva, I; DeRyke, CA; Hawser, SP; Lob, SH; Motyl, MR; Sahm, DF; Siddiqui, F; Young, K | 1 |
| Böhringer, N; Horst, J; Hübner, J; Kappler, M; Kolberg, L; Kresna, IDM; Liu, Y; Marner, M; Mettal, U; Meyer-Bühn, M; Mihajlovic, S; Schäberle, TF; von Both, U; Wang, L | 1 |
| Amara, M; Barraud, O; Bastide, M; Bernabeu, S; Bille, E; Bonnin, RA; Brun, CL; Cattoir, V; Corvec, S; d'Epenoux, LR; Degand, N; Dortet, L; Emeraud, C; Farfour, E; Fihman, V; Grillon, A; Guillard, T; Isnard, C; Jacquier, H; Janvier, F; Jousset, AB; Laurent, F; Lemonnier, A; Lomont, A; Merens, A; Mizrahi, A; Plouzeau, C; Ranc, AG; Soismier, N; Yin, N; Zahar, JR | 1 |
| Cabot, G; Khajehpour, M; Kim, K; Mark, BL; Oliver, A | 1 |
| Jia, P; Xu, Y; Yang, Q; Yu, W; Zhang, H; Zhu, Y | 1 |
| Ballesta, S; López, CE; López-Cerero, L; Pascual, A; Rojo-Martin, MD; Sánchez-Yebra, W | 1 |
| Arends, SJR; Carvalhaes, CG; Castanheira, M; Mendes, RE; Sader, HS; Shortridge, D | 1 |
| Akrich, B; DeRyke, CA; Hawser, SP; Karlowsky, JA; Lob, SH; Motyl, MR; Sahm, DF; Siddiqui, F; Young, K | 1 |
| Aja-Macaya, P; Alonso-García, I; Arca-Suárez, J; Beceiro, A; Bou, G; Fernández-González, A; Galán-Sánchez, F; González-Mayo, E; Guijarro-Sánchez, P; Lada-Salvador, P; Lasarte-Monterrubio, C; Martínez-Guitián, M; Muíño-Andrade, M; Oliver, A; Rodríguez-Iglesias, M; Rumbo-Feal, S; Vázquez-Ucha, JC; Vela-Fernández, R | 1 |
| Hsueh, PR; Lee, YL | 1 |
| Hsueh, PR; Ko, WC; Lee, YL | 1 |
| Fujimori, T; Hagiya, H; Higashikage, A; Iio, K; Kakehi, A; Minabe, H; Okura, M; Otsuka, F; Yokoyama, Y | 1 |
| Faurholt-Jepsen, D; Jensen, PØ; Johansen, HK; Katzenstein, TL; Kolpen, M; Pressler, T; Qvist, T | 1 |
| Agyeman, AA; Boyce, JD; Bulitta, JB; Cortés-Lara, S; Figuerola, J; Fraile-Ribot, P; Franklyn, ERT; Gomis-Font, MA; Landersdorfer, CB; Lang, Y; Lee, WL; López-Causapé, C; Lucas, DD; Nation, RL; Oliver, A; Rogers, KE; Zhang, Y; Zhou, J | 1 |
| Abbott, IJ; Chang, CC; Dennison, A; Kostoulias, X; Peleg, AY; Spelman, DW; Wisniewski, J; Zisis, H | 1 |
| Al Musawa, M; Alanazi, MQ; Alassiri, D; Alfahad, W; Alghaith, J; Alharbi, A; Aljefri, D; Aljurbua, A; Almangour, TA; Almohaizeie, A; Almuhisen, S; Alsowaida, YS; Damfu, N; Ghonem, L; Khormi, Y | 1 |
| Chen, WT; Cheng, MH; Hsieh, TC; Karlowsky, JA; Lu, HC; Motyl, MR; Sahm, DF; Siddiqui, F; Wise, MG; Young, K | 1 |
| Albur, M; Attwood, M; Griffin, P; Macgowan, AP; Noel, AR | 1 |
| Autmizguine, J; Kassir, N; Lavigne, J; Litalien, C; Théorêt, Y; Thibault, C | 1 |
| Bou, G; Cabot, G; Cortes-Lara, S; Del Barrio-Tofiño, E; López-Causapé, C; Martínez-Martínez, L; Oliver, A; Sánchez-Diener, I; Zamorano, L | 1 |
| Abdel Hadi, H; Abu Jarir, S; Al-Maslamani, MA; Bonomo, RA; Dousa, KM; Eltai, NO; Hassan, AAI; Hujer, AM; Ibrahim, EB; Jass, J; Omrani, AS; Sid Ahmed, MA; Soderquist, B; Sultan, AA | 1 |
| Bonomo, RA; Davis, SL; Dhar, S; File, TM; Gerlach, AT; Kaye, KS; Olson, S; Patel, TS; Perez, F; Pogue, JM; Puzniak, LA; Veve, MP | 1 |
| Flamm, RK; Pfaller, MA; Shortridge, D; Streit, JM | 1 |
| Buonomo, AR; Gentile, I; Maraolo, AE; Mazzitelli, M; Torti, C; Trecarichi, EM | 1 |
| Alves, V; Cantón, R; Chaves, C; Diogo, J; Ferreira, R; García-Castillo, M; García-Fernández, S; Gonçalves, E; Melo-Cristino, J; Paixão, L; Pássaro, L; Pinto, MF; Ramalheira, E; Sancho, L; Silva, D; Vieira, AR | 1 |
| Buonomo, AR; Congera, P; Foggia, M; Gentile, I; Maraolo, AE; Parente, S; Scotto, R; Zappulo, E | 1 |
| Abdulhamid, I; Ang, JY; Molloy, L; Srivastava, R | 1 |
| Kharat, AS; Khobragade, K; Palwe, S; Periasamy, H; Veeraraghavan, B | 1 |
| Cabot, G; Fernández-Esgueva, M; Fraile-Ribot, PA; Huarte, R; López-Calleja, AI; Mulet, X; Oliver, A; Rezusta, A | 1 |
| Juhász, E; Katona, K; Kristóf, K; Melegh, S; O'Neall, D; Szabó, J; Tóth, Á; Urbán, E | 1 |
| Amore, D; Anile, M; Bassi, M; Cagnetti, S; Carillo, C; D'Agostino, FG; De Giacomo, T; Diso, D; Mantovani, S; Mottola, E; Pagini, A; Pecoraro, Y; Poggi, C; Pugliese, F; Rendina, EA; Russo, G; Vannucci, J; Venuta, F | 1 |
| Cayô, R; Cuba, GT; Gales, AC; Kiffer, CRV; Nicolau, DP; Nodari, CS; Pignatari, ACC; Rocha-Santos, G; Streling, AP | 1 |
| DePestel, DD; Karlowsky, JA; Lob, SH; Motyl, MR; Raddatz, J; Sahm, DF; Young, K | 1 |
| Gatermann, SG; Körber-Irrgang, B; Korte-Berwanger, M; Kresken, M; Pfennigwerth, N; Seifert, H | 1 |
| Adamou, P; Antoniadou, A; Damala, M; Deliolanis, I; Fountoulis, K; Galani, I; Galani, L; Giamarellou, H; Karaiskos, I; Karantani, I; Kirikou, H; Kodonaki, A; Maraki, S; Markopoulou, M; Papadogeorgaki, E; Papoutsaki, V; Petinaki, E; Prifti, E; Souli, M; Tsiplakou, S; Vagiakou, E | 1 |
| Arends, SJR; Duncan, LR; Flamm, RK; Pfaller, MA; Shortridge, D; Streit, JM | 1 |
| Carvalhaes, CG; Duncan, LR; Flamm, RK; Sader, HS; Shortridge, D | 1 |
| Bisanti, A; Diaz, E; Martin-Loeches, I; Rodriguez, A | 1 |
| Bidell, MR; Lodise, TP; O'Donnell, JN | 1 |
| Arca-Suárez, J; Beceiro, A; Bou, G; Cabot, G; Fraile-Ribot, PA; Galán-Sánchez, F; González-Bello, C; Lasarte-Monterrubio, C; Lence, E; Martínez-Guitián, M; Oliver, A; Rodríguez-Iglesias, M; Vázquez-Ucha, JC | 1 |
| Forland, SC; Guerrero-Wooley, RL; Hino, G; Park, SH; Winans, SA | 1 |
| Avdic, E; Beisken, S; Bergman, Y; Cosgrove, SE; Posch, AE; Sharara, SL; Simner, PJ; Tamma, PD | 1 |
| Bookstaver, PB; Bouchard, J; Gould, AP; Hucks, J; Justo, JA; Nelson, D; Nicolau, D; O'Neal, M; Sheffield, M | 1 |
| Bacca, E; Bedini, A; Bianco, V; Cuomo, G; Franconi, I; Meschiari, M; Mussini, C; Orlando, G | 1 |
| Arca-Suárez, J; Beceiro, A; Bou, G; Cabot, G; Galán-Sánchez, F; González-Bello, C; Lasarte-Monterrubio, C; Oliver, A; Rodiño-Janeiro, BK; Rodríguez-Iglesias, M; Vázquez-Ucha, JC | 1 |
| Alves, V; Bou, G; Cantón, R; Cercenado, E; Chaves, C; Delgado-Valverde, M; Díaz-Regañón, J; Diogo, J; Ferreira, R; García-Castillo, M; García-Fernández, S; Gonçalves, E; Hernández-García, M; López-Mendoza, D; Melo-Cristino, J; Oliver, A; Paixão, L; Pássaro, L; Pinto, MF; Pitart, C; Ramalheira, E; Rodríguez-Lozano, J; Romano, J; Sancho, L; Silva, T; Tormo, N; Vieira, AR | 1 |
| Cohen, L; Finklea, JD; Jain, R; Nolan, PJ; Smith, TT | 1 |
| Asensio-Martín, MJ; Balandin, B; Ballesteros, D; Chicot, M; Fernández-Simón, I; Iranzo, R; López-Vergara, L; Martínez-Sagasti, F; Pérez-Pedrero, MJ; Pintado, V; Rodríguez-Serrano, D; Royuela, A; Ruiz de Luna, R; Sancho-González, M; Silva, A; Soriano-Cuesta, C | 1 |
| Arend, LNVS; Bail, L; Ito, CAS; Nogueira, KDS; Tuon, FF | 1 |
| Bruno, C; Carmelitano, P; Castanheira, M; De Anda, C; Huntington, JA; Johnson, MG; Motyl, M; Rhee, EG; Yu, B | 1 |
| Khan, S; Phe, K; Tam, VH | 1 |
| Arcay, RM; Cantón, R; Castillo, FJ; Cercenado, E; Cisterna, R; Díaz-Regañón, J; Gálvez-Benítez, L; González Romo, F; Hernández-Cabezas, A; López-Mendoza, D; Loza, E; Rodríguez-Lozano, J; Suárez-Barrenechea, AI; Tubau, F | 1 |
| Baccani, I; Bartalesi, F; Bartoloni, A; Borchi, B; Bresci, S; Cavallo, A; Ottino, L; Rossolini, GM | 1 |
| Sivashanmugam, K; Srivastava, P | 1 |
| Collings, H; Dillon, R; Enstone, A; Palmer, T; Puzniak, L | 1 |
| Murri, R; Sacco, E | 1 |
| Betthauser, KD; Kollef, MH; Lizza, BD; Micek, ST; Ritchie, DJ | 1 |
| Barrio-Tofiño, ED; Cortes-Lara, S; López-Causapé, C; Oliver, A | 1 |
| Akrich, B; Amode, A; Berthelot, A; Boutoille, D; Castan, B; Levy-Bachelot, L; Mackosso, C; Mathis, L; Mootien, J; Ruimy, R; Ruiz, F; Timsit, JF | 1 |
| Cazorla-Poderoso, L; Huarte-Lacunza, R; Larrodé-Leciñena, I; López-Calleja, AI; Magallón-Martínez, A; Martínez-Álvarez, RM; Pereira-Blanco, O; Pérez-Moreno, M; Pinilla-Rello, A | 1 |
| Daragon, B; Fournier, D; Jeannot, K; Plésiat, P | 1 |
| Cantón, R; García-Castillo, M; García-Fernández, S; Hernández-García, M; Pássaro, L | 1 |
| Abbo, LM; Adachi, J; Aitken, SL; Araos, R; Arias, CA; Bonomo, RA; Jain, R; Lichtenberger, PN; Miller, WR; Munita, JM; Nigo, M; Perez, F; Rakita, R; Rosa, R; Shelburne, S; Shimose, LA; Tran, TT; Wanger, A | 1 |
| Álvarez Lerma, F; Gracia Arnillas, MP; Grau, S; Mico García, M; Muñoz Bermudez, R; Recasens, L; Sorli, L | 1 |
| Berenson, CS; Kurtzhalts, KE; Manohar, A; Mergenhagen, KA | 1 |
| Béraud, G; Bouchand, F; Canouï, E; Davido, B; Dinh, A; Duran, C; Ferry, T; Hénard, S; Kernéis, S; Lazaro, P; Lebeaux, D; Wolff, M; Wyplosz, B | 1 |
| Bassetti, M; Castaldo, N; Givone, F; Peghin, M; Righi, E; Sartor, A | 1 |
| Borgia, G; Buonomo, AR; De Zottis, F; Di Renzo, G; Gentile, I; Maraolo, AE; Scotto, R | 1 |
| Grupper, M; Nicolau, DP; Sutherland, C | 1 |
| Borgia, G; Cascella, M; Corcione, S; Cuomo, A; De Rosa, FG; Gentile, I; Maraolo, AE; Nappa, S | 1 |
| Goodlet, KJ; Nailor, MD; Nicolau, DP | 1 |
| Chen, L; Kreiswirth, BN; MacVane, SH; Pandey, R; Steed, LL | 1 |
| Becker, K; Bletz, S; Idelevich, EA; Mellmann, A; Schaumburg, F | 1 |
| Bodro, M; Marco, F; Martínez, JA; Soriano, A; Xipell, M | 1 |
| Hindler, JA; Humphries, RM; Miller, SA; Wong-Beringer, A | 1 |
| Cheng, S; Clancy, CJ; Cooper, VS; Doi, Y; Haidar, G; Hao, B; Nguyen, MH; Philips, NJ; Potoski, BA; Press, EG; Shields, RK; Snyder, D | 1 |
| Castanheira, M; Flamm, RK; Pfaller, MA; Shortridge, D | 2 |
| Bassetti, M; Castaldo, N; Givone, F; Lechiancole, A; Livi, U; Maiani, M; Pea, F; Peghin, M; Righi, E; Sartor, A | 1 |
| Lodise, TP; Natesan, S; Pai, MP | 1 |
| Lasco, TM; Ledesma, KR; Skoglund, E; Tam, VH | 1 |
| Cabot, G; Fraile-Ribot, PA; Juan, C; Martín-Pena, ML; Mulet, X; Oliver, A; Pérez, JL; Periañez, L | 1 |
| Arcenillas, P; Boix-Palop, L; Calbo, E; Cuchi, E; Dietl, B; Gómez, L; González de Molina, FJ; Nicolás, J; Sánchez, I | 1 |
| Arena, F; Bassetti, M; D'Andrea, MM; Di Pilato, V; Giani, T; Henrici De Angelis, L; Pollini, S; Rossolini, GM | 1 |
| Adam, H; Baxter, M; Hoban, DJ; Karlowsky, JA; Lagacé-Wiens, P; Walkty, A; Zhanel, GG | 2 |
| Castanheira, M; Duncan, LR; Mendes, RE; Sader, HS; Shortridge, D | 1 |
| Monogue, ML; Nicolau, DP | 1 |
| Bodro, M; Fresco, L; Marco, F; Martínez, JA; Paredes, S; Soriano, A; Xipell, M | 1 |
| Hakki, M; Lewis, JS | 1 |
| Allworth, AM; Legg, A; McCarthy, KL; Roberts, JA; Stewart, A; Wallis, SC | 1 |
| Bassetti, M; De Rosa, FG; Del Bono, V; Giacobbe, DR; Grossi, PA; Menichetti, F; Pea, F; Rossolini, GM; Tumbarello, M; Viale, P; Viscoli, C | 1 |
| Almirante, B; Arévalo, Á; Campany, D; Escolà-Vergé, L; Ferrer, R; Larrosa, N; Len, O; Los-Arcos, I; Nuvials, X; Pigrau, C; Viñado, B | 1 |
| Caro, L; Huntington, JA; Long, J; Xiao, AJ | 1 |
| Chaves, F; Lora-Tamayo, J; Orellana, MÁ; Recio, R; Viedma, E; Villa, J | 1 |
| Alessa, MA; Alhokail, M; Alhossan, A; Alkholief, MA; Almangour, TA; Tabb, DE | 1 |
| Dunn, A; Plant, AJ; Porter, RJ | 1 |
| Finklea, JD; Hollaway, R; Jain, R; Le, J; Lee, F; Lowe, K | 1 |
| Jones, AL; Lee, AC | 1 |
| Jiménez-Delgado, JD; Monterrubio-Villar, J; Rodríguez-Garrido, S | 1 |
| Asensio, J; Ayestarán, I; Colomar, A; Delgado, O; Díaz-Cañestro, M; Fraile-Ribot, PA; López-Causapé, C; Maciá, M; Martin-Pena, ML; Mulet, X; Murillas, J; Novo, A; Nuñez, B; Oliver, A; Pérez, JL; Periañez, L; Riera, M; Torres, V | 1 |
| Bonomo, RA; Chambers, HF; Chen, L; Domitrovic, TN; Evans, SR; Farmer, M; Fowler, VG; Hill, CB; Hujer, AM; Hujer, KM; Jacobs, MR; Kreiswirth, BN; Manca, C; Mediavilla, JR; Patel, R; Perez, F; Pitzer, KM; Tran, TTT; Wilson, BM | 1 |
| Galega, R; Greene, JN; Lee, GC; Quilitz, R; Shurko, J; So, W | 1 |
| Bassetti, M; Montravers, P | 1 |
| Dubois, V; Jayol, A; Kieffer, N; Nordmann, P; Ortiz De La Rosa, JM; Poirel, L | 1 |
| Henderson, A; McCarthy, KL; Paterson, DL; Tan, E | 1 |
| Artioli, S; Bassetti, M; Capone, A; Carannante, N; Castaldo, N; Cattelan, A; Cipriani, L; Coletto, D; Digaetano, M; Grossi, P; Losito, AR; Mastroianni, CM; Menichetti, F; Mussini, C; Nicolè, S; Peghin, M; Righi, E; Russo, A; Tascini, C; Tumbarello, M; Vena, A | 1 |
| Fernández Esgueva, M; Ferrer Cerón, I; García-Lechuz Moya, JM; López-Calleja, AI; Morilla Morales, E; Nuñez Medina, R; Rezusta López, A; Sahagún Pareja, J; Viñuelas Bayon, J | 1 |
| Basak, GW; Saran, O; Sulik-Tyszka, B; Wróblewska, MM | 1 |
| Arena, F; Cassetta, MI; Contorni, M; Henrici De Angelis, L; Maglioni, E; Marchetti, L; Novelli, A; Rossolini, GM | 1 |
| Ariza, J; Benavent, E; El Haj, C; Gómez-Junyent, J; Murillo, O; Rigo-Bonnin, R; Sierra, Y; Soldevila, L; Torrejón, B; Tubau, F | 1 |
| Blázquez-Gamero, D; Brañas, P; Epalza, C; Flores, M; Grau, S; Martín-Cazaña, M; Olmedilla, M | 1 |
| Di Bonaventura, G; Fiscarelli, E; Gherardi, G; Linardos, G; Pompilio, A | 1 |
| Aitken, E; Gould, IM; Hijazi, K; Joshi, C; Oggioni, MR; Zamudio, R | 1 |
| Hesford, C; Nakhosteen, A; Sayma, M; Tariq, Z; Walters, HR | 1 |
| Avery, LM; Nicolau, DP; Sutherland, CA | 1 |
| Akova, M; Albasanz-Puig, A; Araos, R; Bote, A; Brunel, AS; Calik, S; Carratalà, J; Del Pozo, JL; Drgona, L; García, E; Gomes, MZR; Gudiol, C; Hemmati, P; Herrera, F; Ibrahim, KY; Isler, B; Kanj, S; Kern, W; Maestro de la Calle, G; Manzur, A; Marin, JI; Márquez-Gómez, I; Martín-Dávila, P; Mikulska, M; Montejo, JM; Montero, M; Morales, HMP; Morales, I; Novo, A; Oltolini, C; Parody, R; Peghin, M; Puerta-Alcalde, P; Ruiz-Camps, I; Sipahi, OR; Tebe, C; Tilley, R; Yáñez, L | 1 |
| Nordmann, P; Ortiz de la Rosa, JM; Poirel, L | 1 |
| Li, J; Ma, W; Sun, S; Wang, D; Yu, C | 1 |
| Ann Justo, J; Bookstaver, PB; Elizabeth Davis, S; Foster, R; Gould, A; Ham, J; Hucks, J; Nicolau, DP | 1 |
| Boulanger, B; Cizeau, F; Decousser, JW; Ducellier, D; Fourreau, F; Mercier-Darty, M; Mongardon, N; Podglajen, I; Potron, A; Royer, G | 1 |
| Arca-Suárez, J; Beceiro, A; Bou, G; Cabot, G; Fraile-Ribot, P; Galán-Sánchez, F; González-Bello, C; Lence, E; Martínez-Guitián, M; Oliver, A; Rodríguez-Iglesias, M; Vázquez-Ucha, JC | 1 |
| Bruchmann, S; Cabot, G; Haussler, S; Juan, C; Moyà, B; Mulet, X; Oliver, A; Zamorano, L | 1 |
| Aghazadeh, M; Hojabri, T; Hojabri, Z; Mahdian, R; Nahaei, MR; Pajand, O; Pirzadeh, T; Rahmati, M | 1 |
| Castanheira, M; Farrell, DJ; Flamm, RK; Jones, RN; Sader, HS | 1 |
| Dietrich, KA; Herzinger, T; Ruzicka, T | 1 |
| Cleveland, KO; Gelfand, MS | 1 |
| Chahine, EB; Cogan, P; Fete, M; Sucher, AJ | 1 |
| Bofarull, AM; Cantón, R; García-Castillo, M; Tato, M | 1 |
| Gonzales, JP; Heil, EL; Mehrotra, S; Nicolau, DP; Oliver, WD; Robinett, K; Saleeb, P | 1 |
| Akiyama, K; Hamaoka, S; Katoh, H; Kinoshita, M; Naito, Y; Sawa, T; Shimizu, M | 1 |
| Greenwood-Quaintance, KE; Karau, MJ; Kohner, PC; Patel, R; Schmidt-Malan, SM; Velez Perez, AL | 1 |
| Aitken, SL; Bhatti, MM; DePombo, AM; Gettys, SC; Kontoyiannis, DP; Nicolau, DP; Nunez, CA; Tverdek, FP | 1 |
| Ghazi, IM; Kuti, JL; Nicolau, DP; Quintiliani, R; Shore, E | 1 |
| Choudhary, S; Makwana, M; Soni, JP; Tripathi, N | 1 |
| McClain, D; Vickery, SB; Wargo, KA | 1 |
| Cies, JJ; Kuti, JL; Monogue, ML; Muhlebach, M; Nicolau, DP; Pettit, RS | 1 |
| Borgia, G; Gentile, I; Maraolo, AE | 1 |
| Abdel-Haq, N; Ang, JY; Nicolau, DP; Satlin, MJ; Thabit, AK; van Duin, D; Zhu, F | 1 |
| Algora-Weber, A; de la Calle-Pedrosa, N; Delgado-Iribarren, A; Gabán-Díez, Á; González-Jiménez, AI; Hernández-Tejedor, A; Martín-Vivas, A; Merino-Vega, CD; Ruiz de Luna-González, R; Temprano-Gómez, I | 1 |
| Castón, JJ; De la Torre, Á; Ruiz-Camps, I; Sorlí, ML; Torre-Cisneros, J; Torres, V | 1 |
| Crespo Casal, M; Martinez-Lamas, L; Nodar, A; Perez-Landeiro, A; Perez-Rodríguez, MT; Sousa Dominguez, A | 1 |
| Brockhurst, MA; Davies, EV; James, CE; Winstanley, C | 1 |
| Bassetti, M; Castanheira, M; Duncan, LR; Pfaller, MA | 1 |
| Gillani, SJH; Jielani, A; Naqvi, SAR; Rasheed, R; Saeed, N; Zahoor, AF | 1 |
| Fujimura, S; Nakano, Y; Takane, H; Watanabe, A | 1 |
| Albertí, S; Juan, C; Mulet, X; Oliver, A; Pérez, JL; Zamorano, L | 1 |
| Bulik, CC; Keel, RA; Nicolau, DP; Sutherland, CA; Tessier, PR | 1 |
| Andes, DR; Craig, WA | 1 |
| Kaygusuz, A | 1 |
| Kuti, JL; Nicolau, D; Nightingale, CH; Quintiliani, R | 1 |
| Akgün, H; Caner, F; Erkiliç, K; Eşel, D; Evereklioglu, C; Ozkiriş, A | 1 |
| Akgün, H; Erkiliç, K; Esel, D; Evereklioglu, C; Göktas, S; Ozkiris, A | 1 |
| Hameed, S; Johnson, M; Lipman, M; Tariq, S; Tyrer, M | 1 |
| Pang, XY; Tian, BW; Yang, YJ | 1 |
| Alireza, S; Gholamali, G; Javad, A; Kazem, G; Qulamreza, K; Vahid, P | 1 |
| Leitner, E; Lode, H; Schmitt, DV; Welte, T | 1 |
| Tucker, H; Wu, D | 1 |
| Ikonomidis, A; Kantzanou, M; Maniatis, AN; Neou, E; Pournaras, S; Tsakris, A | 1 |
| Ambrosetti, P; Aymon, D; Bille, J; Chiolero, R; Cometta, A; Glauser, MP; Harbarth, S; Huber, O; Jaccard, C; Lew, D; Praz, G; Ricou, B; Romand, J; Schneider, R; Troillet, N; Zanetti, G | 1 |
| Burgess, DS; Hastings, RW | 1 |
| Coia, JE; Gillespie, TA; Hanson, MF; Johnson, PR; Notman, AW | 1 |
| Harris, AD; Johnson, JA; Kaye, KS; Morris, G; Perencevich, E; Roghmann, MC | 1 |
13 review(s) available for tazobactam and Pseudomonas Infections
| Article | Year |
|---|---|
Ceftolozane-tazobactam: When, how and why using it?
Topics: Anti-Bacterial Agents; Cephalosporins; Colistin; Humans; Intraabdominal Infections; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Ceftolozane-tazobactam in nosocomial pneumonia.
Topics: Adult; Cephalosporins; Cross Infection; Healthcare-Associated Pneumonia; Humans; Pseudomonas Infections; Tazobactam | 2022 |
Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Intraabdominal Infections; Observational Studies as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Soft Tissue Infections; Tazobactam; Urinary Tract Infections | 2020 |
Approach to the Treatment of Patients with Serious Multidrug-Resistant Pseudomonas aeruginosa Infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Use of continuous-infusion ceftolozane/tazobactam for resistant Gram-negative bacterial infections: a retrospective analysis and brief review of the literature.
Topics: Adult; Aged; Anti-Bacterial Agents; Area Under Curve; beta-Lactamase Inhibitors; Cephalosporins; Drug Combinations; Drug Monitoring; Humans; Infusions, Intravenous; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam; Young Adult | 2020 |
Ceftazidime/avibactam and ceftolozane/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Male; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Real-world use of ceftolozane/tazobactam: a systematic literature review.
Topics: Cephalosporins; Comorbidity; Critical Illness; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacterial Infections; Humans; Intraabdominal Infections; Pseudomonas Infections; Respiratory Tract Infections; Tazobactam; Urinary Tract Infections | 2021 |
New Perspectives on Antimicrobial Agents: Ceftolozane-Tazobactam.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Critical Illness; Disease Management; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Intensive Care Units; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Tazobactam; Treatment Outcome | 2017 |
Ceftolozane/tazobactam: place in therapy.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Intraabdominal Infections; Off-Label Use; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Urinary Tract Infections | 2018 |
Multi-resistant Pseudomonas aeruginosa ST235 in cystic fibrosis.
Topics: Anti-Bacterial Agents; Cephalosporins; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Prognosis; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome | 2018 |
The ideal patient profile for new beta-lactam/beta-lactamase inhibitors.
Topics: Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenem-Resistant Enterobacteriaceae; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae Infections; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2018 |
Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Clinical Trials as Topic; Drug Combinations; Drug Interactions; Drug Resistance, Bacterial; Humans; Intraabdominal Infections; Mice; Penicillanic Acid; Pseudomonas Infections; Tazobactam; Urinary Tract Infections | 2015 |
4 trial(s) available for tazobactam and Pseudomonas Infections
| Article | Year |
|---|---|
Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP).
Topics: Anti-Bacterial Agents; Bacterial Proteins; Cephalosporins; DNA, Bacterial; Double-Blind Method; Drug Resistance, Bacterial; Healthcare-Associated Pneumonia; Humans; Meropenem; Multicenter Studies as Topic; Multilocus Sequence Typing; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory System; Tazobactam; Treatment Outcome | 2021 |
Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation.
Topics: Acute Disease; Adolescent; Adult; Anti-Bacterial Agents; Cephalosporins; Cystic Fibrosis; Female; Humans; Infusions, Intravenous; Lung; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Patient Safety; Penicillanic Acid; Pneumonia, Bacterial; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Tazobactam | 2016 |
Piperacillin/tazobactam vs imipenem/cilastatin in the treatment of nosocomial pneumonia--a double blind prospective multicentre study.
Topics: Adult; Cilastatin; Cross Infection; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Imipenem; Male; Penicillanic Acid; Piperacillin; Pneumonia; Prospective Studies; Pseudomonas Infections; Tazobactam; Treatment Outcome | 2006 |
Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis.
Topics: Acute Disease; Adult; Aged; Cilastatin; Cilastatin, Imipenem Drug Combination; Cross Infection; Drug Combinations; Drug Therapy, Combination; Female; Humans; Imipenem; Male; Middle Aged; Penicillanic Acid; Peritonitis; Piperacillin; Pneumonia; Prospective Studies; Pseudomonas Infections; Tazobactam | 1998 |
179 other study(ies) available for tazobactam and Pseudomonas Infections
| Article | Year |
|---|---|
Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; beta-Lactamases; Catheters, Indwelling; Chromosomes, Bacterial; Cloning, Molecular; Electrophoresis, Gel, Pulsed-Field; Genes, Bacterial; Genetic Variation; Isoelectric Focusing; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Phylogeny; Plasmids; Pseudomonas; Pseudomonas Infections; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Substrate Specificity | 2010 |
BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
Topics: Belgium; beta-Lactamases; Cephalosporinase; Cephalosporins; Cross Infection; Escherichia coli; Genes, Bacterial; Humans; Kinetics; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2010 |
GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamases; beta-Lactams; Cephalosporins; Genetic Variation; Humans; Integrons; Microbial Sensitivity Tests; Molecular Sequence Data; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA | 2010 |
Pharmaceutical Approaches to Target Antibiotic Resistance Mechanisms.
Topics: Azabicyclo Compounds; beta-Lactamase Inhibitors; Drug Resistance, Microbial; Enterobacteriaceae Infections; Humans; Imipenem; Pseudomonas Infections | 2017 |
Ceftolozane/tazobactam for refractory P. aeruginosa endocarditis: A case report and pharmacokinetic analysis.
Topics: Anti-Bacterial Agents; Cephalosporins; Endocarditis; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Ceftolozane-tazobactam activity against clinical isolates of Pseudomonas aeruginosa from ICU patients with pneumonia: United States, 2015-2018.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Intensive Care Units; Microbial Sensitivity Tests; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; United States | 2021 |
Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa from patients hospitalized with pneumonia in European medical centers in 2020.
Topics: Azabicyclo Compounds; beta-Lactamase Inhibitors; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Hospitalization; Humans; Imipenem; Jupiter; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Boronic Acids; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Soft Tissue Infections; Tazobactam | 2021 |
Impact of ceftolozane/tazobactam concentrations in continuous infusion against extensively drug-resistant Pseudomonas aeruginosa isolates in a hollow-fiber infection model.
Topics: Anti-Bacterial Agents; Cephalosporins; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Real-World Performance of Susceptibility Testing for Ceftolozane/Tazobactam against Non-Carbapenemase-Producing Carbapenem-Resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporins; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
In vitro activity of ceftolozane/tazobactam against Gram-negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries-SMART 2017-2019.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Intensive Care Units; Meropenem; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Tazobactam; Thailand | 2022 |
Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Comparative analysis of in vitro dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Cephalosporins; Clone Cells; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Ceftolozane-tazobactam vs. colistin for the treatment of infections due to multidrug-resistant Pseudomonas aeruginosa: a multicentre cohort study.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2022 |
In-vitro activity of ceftolozane/tazobactam against recent clinical bacterial isolates from two Saudi Arabian hospitals.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Escherichia coli; Hospitals; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Saudi Arabia; Tazobactam | 2022 |
Ceftolozane/tazobactam for difficult-to-treat Gram-negative infections: A real-world tertiary hospital experience.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam; Tertiary Care Centers | 2022 |
Ceftolozane/tazobactam versus colistin in the treatment of ventilator-associated pneumonia due to extensively drug-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2022 |
Drug resistance rates of difficult to treat Pseudomonas aeruginosa isolates to ceftolozane-tazobactam and ceftazidime-avibactam from a tertiary hospital, Singapore.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Cephalosporins; Drug Resistance; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Singapore; Tazobactam; Tertiary Care Centers | 2022 |
Resistance mechanisms and molecular epidemiology of Pseudomonas aeruginosa strains from patients with bronchiectasis.
Topics: Anti-Bacterial Agents; beta-Lactamases; Bronchiectasis; Ceftazidime; Ciprofloxacin; Humans; Microbial Sensitivity Tests; Molecular Epidemiology; Multilocus Sequence Typing; Phylogeny; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Combinations; Hospitals; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; United States | 2022 |
Therapeutic Drug Monitoring and Prolonged Infusions of Ceftolozane/Tazobactam for MDR/XDR Pseudomonas aeruginosa Infections: An Observational Study.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Monitoring; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Clinical and microbiological features of ceftolozane/tazobactam-resistant Pseudomonas aeruginosa isolates in a university hospital in central Italy.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Hospitals; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Borinic Acids; Carboxylic Acids; Cefepime; Cefiderocol; Ceftazidime; Cephalosporins; Cyclooctanes; Humans; Imipenem; Piperidines; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
The plethora of resistance mechanisms in Pseudomonas aeruginosa: transcriptome analysis reveals a potential role of lipopolysaccharide pathway proteins to novel β-lactam/β-lactamase inhibitor combinations.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; Gene Expression Profiling; Humans; Lactams; Lipopolysaccharides; Microbial Sensitivity Tests; Monobactams; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Treatment of multidrug-resistant Pseudomonas aeruginosa bacteremia using ceftolozane-tazobactam-based or colistin-based antibiotic regimens: A multicenter retrospective study.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2022 |
Functional and Structural Characterization of OXA-935, a Novel OXA-10-Family β-Lactamase from Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aspartic Acid; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Ceftazidime; Cephalosporinase; Cephalosporins; Glycine; Humans; Microbial Sensitivity Tests; Phenylalanine; Pseudomonas aeruginosa; Pseudomonas Infections; Serine; Tazobactam | 2022 |
Activity of newest generation β-lactam/β-lactamase inhibitor combination therapies against multidrug resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Lactams; Microbial Sensitivity Tests; Monobactams; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa from patients in the Middle East and Africa - Study for Monitoring Antimicrobial Resistance Trends (SMART) 2017-2020.
Topics: Anti-Bacterial Agents; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
How to Manage Pseudomonas aeruginosa Infections.
Topics: Anti-Bacterial Agents; Carbapenems; Colistin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Fosfomycin; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Ceftolozane/Tazobactam and Ceftazidime/Avibactam: An Italian Multi-center Retrospective Analysis of Safety and Efficacy in Children With Hematologic Malignancies and Multi-drug Resistant Gram-negative Bacteria Infections.
Topics: Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Child; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Hematologic Neoplasms; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2022 |
Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Cefepime; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical gram-negative isolates from Czech Republic, Hungary, and Poland-SMART 2017-2020.
Topics: Anti-Bacterial Agents; Cephalosporins; Czech Republic; Humans; Hungary; Imipenem; Microbial Sensitivity Tests; Poland; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Cefiderocol, and Novel Darobactin Analogs against Multidrug-Resistant Pseudomonas aeruginosa Isolates from Pediatric and Adolescent Cystic Fibrosis Patients.
Topics: Adolescent; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Child; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Evaluation of ceftolozane-tazobactam susceptibility on a French nationwide collection of Enterobacterales.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Enterobacteriaceae; Escherichia coli; Humans; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Biochemical Insights into Imipenem Collateral Susceptibility Driven by
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Imipenem; Microbial Sensitivity Tests; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa collected in the Study for Monitoring Antimicrobial Resistance Trends (SMART) between 2016 and 2019 in China.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Evaluation of three commercial methods of susceptibility testing for ceftolozane/tazobactam against carbapenem-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Carbapenems; Cross Infection; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Ceftazidime; Cephalosporins; Drug Combinations; Hospitals; Humans; Imipenem; Lactams; Meropenem; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
In vitro activity of ceftolozane/tazobactam against multidrug-resistant Pseudomonas aeruginosa from patients in Western Europe: SMART 2017-2020.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Ceftazidime; Cephalosporinase; Cephalosporins; Drug Combinations; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Poor in vitro activity of ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam against carbapenem-resistant Pseudomonas aeruginosa in India: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2018-2021.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Leadership; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
In vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveil
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Doripenem; Humans; Imipenem; Leadership; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Susceptibility of ceftolozane/tazobactam against multidrug-resistant and carbapenem-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Antimicrobial resistance of Pseudomonas aeruginosa in a cystic fibrosis population after introduction of a novel cephalosporin/β-lactamase inhibitor combination.
Topics: Adult; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporinase; Cephalosporins; Cystic Fibrosis; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Monobactams; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Ceftolozane/tazobactam plus tobramycin against free-floating and biofilm bacteria of hypermutable Pseudomonas aeruginosa epidemic strains: Resistance mechanisms and synergistic activity.
Topics: Adolescent; Anti-Bacterial Agents; Biofilms; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Tobramycin | 2023 |
Antimicrobial susceptibility of ceftolozane-tazobactam against multidrug-resistant Pseudomonas aeruginosa isolates from Melbourne, Australia.
Topics: Adult; Anti-Bacterial Agents; Australia; Cephalosporins; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Ceftolozane-Tazobactam Versus Ceftazidime-Avibactam for the Treatment of Infections Caused by Multidrug-Resistant Pseudomonas aeruginosa: a Multicenter Cohort Study.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Cohort Studies; Drug Combinations; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2023 |
Temporal and geographical prevalence of carbapenem-resistant Pseudomonas aeruginosa and the in vitro activity of ceftolozane/tazobactam and comparators in Taiwan-SMART 2012-2021.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Enterobacteriaceae; Humans; Prevalence; Pseudomonas aeruginosa; Pseudomonas Infections; Taiwan; Tazobactam | 2023 |
Antibacterial effect of seven days exposure to ceftolozane-tazobactam as monotherapy and in combination with fosfomycin or tobramycin against Pseudomonas aeruginosa with ceftolozane-tazobactam MICs at or above 4 mg/l in an in vitro pharmacokinetic model.
Topics: Anti-Bacterial Agents; Cephalosporins; Fosfomycin; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Tobramycin | 2023 |
Population Pharmacokinetics and Safety of Piperacillin-Tazobactam Extended Infusions in Infants and Children.
Topics: Anti-Bacterial Agents; Child; Child, Preschool; Cross Infection; Female; Humans; Infant; Male; Microbial Sensitivity Tests; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2019 |
Association between Pseudomonas aeruginosa O-antigen serotypes, resistance profiles and high-risk clones: results from a Spanish nationwide survey.
Topics: Anti-Bacterial Agents; Cephalosporins; Computer Simulation; Cross Infection; Drug Resistance, Multiple, Bacterial; Genotype; Hospitals; Humans; Microbial Sensitivity Tests; O Antigens; Phenotype; Pseudomonas aeruginosa; Pseudomonas Infections; Public Health Surveillance; Serogroup; Serotyping; Spain; Tazobactam; Whole Genome Sequencing | 2019 |
Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Qatar; Tazobactam; Whole Genome Sequencing | 2019 |
Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa.
Topics: Aminoglycosides; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pharmaceutical Preparations; Polymyxins; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2020 |
Antimicrobial activity of ceftolozane/tazobactam tested against contemporary (2015-2017) Pseudomonas aeruginosa isolates from a global surveillance programme.
Topics: Asia; Cephalosporins; Europe; Female; Global Health; Humans; Latin America; Male; Microbial Sensitivity Tests; North America; Pacific Islands; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Public Health Surveillance; Sepsis; Skin Diseases, Bacterial; Tazobactam | 2020 |
In vitro activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa causing urinary, intra-abdominal and lower respiratory tract infections in intensive care units in Portugal: The STEP multicenter study.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Intensive Care Units; Intraabdominal Infections; Portugal; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Tazobactam; Urinary Tract Infections | 2020 |
Efficacy and safety of ceftolozane/tazobactam as therapeutic option for complicated skin and soft tissue infections by MDR/XDR Pseudomonas aeruginosa in patients with impaired renal function: a case series from a single-center experience.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Humans; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Skin Diseases, Bacterial; Soft Tissue Infections; Tazobactam; Treatment Outcome | 2020 |
Ceftolozane/Tazobactam Treatment of Multidrug-resistant Pseudomonas aeruginosa Infections in Children.
Topics: Adolescent; Anti-Bacterial Agents; Case-Control Studies; Cephalosporins; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Female; Humans; Infant; Male; Microbial Sensitivity Tests; Neutropenia; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome; Young Adult | 2020 |
Unorthodox Parenteral β-Lactam and β-Lactamase Inhibitor Combinations: Flouting Antimicrobial Stewardship and Compromising Patient Care.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Antimicrobial Stewardship; beta-Lactamase Inhibitors; Cephalosporins; China; Drug Combinations; Drug Misuse; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Inappropriate Prescribing; India; Microbial Sensitivity Tests; Patient Care; Pseudomonas aeruginosa; Pseudomonas Infections; Sulbactam; Tazobactam | 2020 |
Characterization of AmpC β-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Microbial Sensitivity Tests; Multilocus Sequence Typing; Mutation; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Ceftazidime-avibactam and ceftolozane-tazobactam susceptibility of multidrug resistant Pseudomonas aeruginosa strains in Hungary.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Hungary; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Use of Ceftazidime-Avibactam and Ceftolozane-Tazobactam After Lung Transplantation.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Klebsiella Infections; Klebsiella pneumoniae; Lung Transplantation; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
In vitro synergy of ceftolozane/tazobactam in combination with fosfomycin or aztreonam against MDR Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aztreonam; Cephalosporins; Fosfomycin; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United State
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Cephalosporins; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Microbial Sensitivity Tests; Phenotype; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; United States | 2021 |
Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany.
Topics: Aged; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Germany; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
In vitro activity of ceftolozane/tazobactam alone and in combination with amikacin against MDR/XDR Pseudomonas aeruginosa isolates from Greece.
Topics: Amikacin; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Greece; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Activity of ceftolozane-tazobactam and comparators when tested against bacterial surveillance isolates collected from patients at risk of infections caused by resistant gram-negative pathogens.
Topics: Aged; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Immunocompromised Host; Inpatients; Intensive Care Units; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012-18.
Topics: Anti-Bacterial Agents; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Europe; Europe, Eastern; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Ceftolozane and tazobactam for the treatment of hospital acquired pneumonia.
Topics: Anti-Bacterial Agents; Cephalosporins; Healthcare-Associated Pneumonia; Humans; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane/tazobactam during treatment of an MDR Pseudomonas aeruginosa infection.
Topics: Anti-Bacterial Agents; Cephalosporins; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Continuous infusion of ceftolozane-tazobactam resulted in high cerebrospinal fluid concentrations of ceftolozane in a patient with multidrug-resistant Pseudomonas aeruginosa meningitis.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Meningitis; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Modifiable Risk Factors for the Emergence of Ceftolozane-tazobactam Resistance.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Tazobactam | 2021 |
Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Distinct epidemiology and resistance mechanisms affecting ceftolozane/tazobactam in Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal depicted by WGS.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Intensive Care Units; Microbial Sensitivity Tests; Portugal; Pseudomonas aeruginosa; Pseudomonas Infections; Spain; Tazobactam | 2021 |
In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against Pseudomonas aeruginosa isolated from patients with cystic fibrosis.
Topics: Adult; Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Combinations; Drug Resistance, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2021 |
Multicenter study of ceftolozane/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Critical Illness; Cross Infection; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Female; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Spain; Tazobactam; Treatment Outcome | 2021 |
The activity of ceftazidime/avibactam against carbapenem-resistant
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenems; Ceftazidime; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Real life experience with ceftolozane/tazobactam therapy for
Topics: Adult; Aged; Anti-Bacterial Agents; APACHE; Bacteremia; Cephalosporins; Comorbidity; Drug Combinations; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Middle Aged; Pseudomonas Infections; Tazobactam | 2021 |
Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018).
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Bacterial; Escherichia coli; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Spain; Tazobactam | 2021 |
Ceftolozane/tazobactam for Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis adult patients: a case series.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Cephalosporins; Cystic Fibrosis; Humans; Italy; Lung; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Tazobactam; Young Adult | 2021 |
Efficacy of sub-MIC level of meropenem and ciprofloxacin against extensive drug-resistant (XDR) Pseudomonas aeruginosa isolates of diabetic foot ulcer patients.
Topics: Anti-Bacterial Agents; Cephalosporins; Ciprofloxacin; Diabetic Foot; Drug Resistance; Humans; Meropenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
What place does ceftolozane/tazobactam have in the treatment of complicated urinary-tract infections?
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Urinary Tract Infections | 2021 |
Predicting Pseudomonas aeruginosa susceptibility phenotypes from whole genome sequence resistome analysis.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Genome, Bacterial; Humans; Meropenem; Microbial Sensitivity Tests; Phenotype; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Real-world evaluation of ceftolozane/tazobactam therapy and clinical outcomes in France.
Topics: Adult; Cephalosporins; Humans; Male; Middle Aged; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
[Utilization study in real clinical practice of ceftolozane/tazobactam vs aminoglycosides and/or colistin in the treatment of multirresistant or extremely resistant Pseudomonas aeruginosa].
Topics: Aftercare; Aged; Aminoglycosides; Anti-Bacterial Agents; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Patient Discharge; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2021 |
Performance of disc diffusion, MIC gradient tests and Vitek 2 for ceftolozane/tazobactam and ceftazidime/avibactam susceptibility testing of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
In vitro characterization of Pseudomonas aeruginosa recovered in Portugal from low respiratory tract infections in ICU patients (STEP Study).
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Intensive Care Units; Microbial Sensitivity Tests; Portugal; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Tazobactam | 2021 |
Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa.
Topics: Adult; Aged; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Female; Humans; Male; Middle Aged; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2017 |
Ceftolozane-tazobactam for the treatment of ventilator-associated infections by colistin-resistant Pseudomonas aeruginosa.
Topics: Acute-Phase Proteins; Aged; Anti-Bacterial Agents; Cephalosporins; Colistin; Drug Resistance, Bacterial; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2017 |
Successful treatment of multidrug-resistant
Topics: Cephalosporins; Cystectomy; Debridement; Drug Resistance, Multiple, Bacterial; Fistula; Humans; Male; Middle Aged; Osteomyelitis; Penicillanic Acid; Pseudomonas Infections; Pubic Symphysis; Tazobactam; Treatment Outcome | 2017 |
Use of ceftolozane/tazobactam as salvage therapy for infections due to extensively drug-resistant Pseudomonas aeruginosa.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Child, Preschool; Drug Resistance, Multiple, Bacterial; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Salvage Therapy; Tazobactam; Treatment Outcome; Young Adult | 2017 |
Multidrug-resistant Pseudomonas aeruginosa skin and soft-tissue infection successfully treated with ceftolozane/tazobactam.
Topics: Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Multiple, Bacterial; Female; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Skin Diseases, Bacterial; Soft Tissue Infections; Tazobactam; Treatment Outcome | 2017 |
Successful treatment of post-surgical osteomyelitis caused by XDR Pseudomonas aeruginosa with ceftolozane/tazobactam monotherapy.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Multiple, Bacterial; Fractures, Bone; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Osteomyelitis; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome | 2017 |
Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Catheter-Related Infections; Ceftazidime; Cephalosporins; Cross Infection; Drug Combinations; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2017 |
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Febrile Neutropenia; Humans; Iatrogenic Disease; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Practice Guidelines as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Tazobactam; Thienamycins; Tobramycin | 2017 |
Emergence of Ceftolozane-Tazobactam-Resistant Pseudomonas aeruginosa during Treatment Is Mediated by a Single AmpC Structural Mutation.
Topics: Aged; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Male; Microbial Sensitivity Tests; Multilocus Sequence Typing; Penicillanic Acid; Polymorphism, Single Nucleotide; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Wound Infection | 2017 |
Susceptibility of MDR Pseudomonas aeruginosa to ceftolozane/tazobactam and comparison of different susceptibility testing methods.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Cephalosporins; Cytoskeletal Proteins; Drug Resistance, Multiple, Bacterial; Germany; Humans; Microbial Sensitivity Tests; Multilocus Sequence Typing; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2017 |
Successful treatment of three severe MDR or XDR Pseudomonas aeruginosa infections with ceftolozane/tazobactam.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Multiple, Bacterial; Drug Synergism; Female; Humans; Male; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome | 2017 |
Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactam Resistance; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporins; Drug Combinations; Gene Expression; Humans; Los Angeles; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2017 |
Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Female; Genome, Bacterial; Humans; Male; Middle Aged; Penicillanic Acid; Pennsylvania; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam; Young Adult | 2017 |
Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazoba
Topics: Amikacin; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Hospitals; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2018 |
Ceftolozane/tazobactam for the treatment of MDR Pseudomonas aeruginosa left ventricular assist device infection as a bridge to heart transplant.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Heart Transplantation; Heart-Assist Devices; Humans; Male; Middle Aged; Penicillanic Acid; Prosthesis-Related Infections; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2018 |
Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L.
Topics: Anti-Bacterial Agents; Cephalosporins; Cross Infection; Drug Combinations; Female; Humans; Infusions, Intravenous; Kidney Function Tests; Male; Microbial Sensitivity Tests; Monte Carlo Method; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2017 |
Ceftolozane/tazobactam activity against meropenem-non-susceptible Pseudomonas aeruginosa bloodstream infection isolates.
Topics: Bacteremia; Cephalosporins; Drug Resistance, Bacterial; Humans; Immunocompromised Host; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2017 |
Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bacterial Typing Techniques; beta-Lactamases; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gene Transfer, Horizontal; Humans; Microbial Sensitivity Tests; Multilocus Sequence Typing; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2018 |
Ceftolozane/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant Pseudomonas aeruginosa: clinical and microbiological outcomes.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Middle Aged; Osteomyelitis; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Skin Diseases, Bacterial; Soft Tissue Infections; Tazobactam; Treatment Outcome | 2018 |
Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers.
Topics: Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactamases; Cephalosporins; Cross Infection; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Epidemiological Monitoring; Humans; Italy; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Tazobactam; Whole Genome Sequencing | 2018 |
In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008-16.
Topics: Canada; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2018 |
Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Gene Expression; Hospitalization; Humans; Isoenzymes; Meropenem; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Plasmids; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory System; Retrospective Studies; Tazobactam; United States | 2018 |
Antibacterial activity of ceftolozane/tazobactam alone and in combination with other antimicrobial agents against MDR Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Multiple, Bacterial; Drug Synergism; Humans; Microbial Sensitivity Tests; Microbial Viability; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2018 |
Clinical experience with ceftolozane/tazobactam in patients with serious infections due to resistant Pseudomonas aeruginosa.
Topics: Aged; Anti-Bacterial Agents; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Retrospective Studies; Tazobactam; Urinary Tract Infections | 2018 |
Ceftolozane-tazobactam therapy for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies and hematopoietic-cell transplant recipients.
Topics: Adult; Aged; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Oregon; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome | 2018 |
Evidence of clinical response and stability of Ceftolozane/Tazobactam used to treat a carbapenem-resistant Pseudomonas Aeruginosa lung abscess on an outpatient antimicrobial program.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Cephalosporins; Humans; Infusions, Parenteral; Lung Abscess; Male; Microbial Sensitivity Tests; Middle Aged; Outpatients; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2018 |
Ceftolozane/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Bacterial; Female; Follow-Up Studies; Humans; Infection Control; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam; Treatment Failure; Treatment Outcome; Young Adult | 2018 |
Ceftolozane/tazobactam dose regimens in severely/morbidly obese patients with complicated intra-abdominal infection or complicated urinary tract infection.
Topics: Anti-Bacterial Agents; Cephalosporins; Computer Simulation; Escherichia coli; Escherichia coli Infections; Female; Humans; Intraabdominal Infections; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Obesity, Morbid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Urinary Tract Infections | 2018 |
Bacteraemia due to extensively drug-resistant Pseudomonas aeruginosa sequence type 235 high-risk clone: Facing the perfect storm.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azabicyclo Compounds; Bacteremia; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; beta-Lactamases; Ceftazidime; Cephalosporins; Clone Cells; Drug Combinations; Drug Resistance, Multiple, Bacterial; Female; Gene Expression; Humans; Male; Middle Aged; Multivariate Analysis; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Retrospective Studies; Survival Analysis; Tazobactam | 2018 |
Ceftolozane-tazobactam for the treatment of multidrug-resistant
Topics: Aged; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Kidney Failure, Chronic; Male; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Renal Dialysis; Tazobactam; Treatment Outcome | 2018 |
Ceftolozane-tazobactam resistance induced in vivo during the treatment of MDR Pseudomonas aeruginosa pneumonia.
Topics: Aged; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Male; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2018 |
Ceftolozane/tazobactam sensitivity patterns in Pseudomonas aeruginosa isolates recovered from sputum of cystic fibrosis patients.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Cross Infection; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Tazobactam | 2018 |
Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa collected from patients with bloodstream infections isolated in United States hospitals (2013-2015) as part of the Program to Assess Ceftolozane-
Topics: Anti-Infective Agents; Bacteremia; Cephalosporins; Enterobacteriaceae; Enterobacteriaceae Infections; Epidemiological Monitoring; Hospitals; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; United States | 2018 |
Postoperative soft-tissue infection due to multidrug-resistant Pseudomonas aeruginosa: usefulness of ceftolozane-tazobactam.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Male; Middle Aged; Postoperative Complications; Pseudomonas aeruginosa; Pseudomonas Infections; Soft Tissue Infections; Tazobactam; Treatment Outcome | 2018 |
Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands.
Topics: Aged; Cephalosporins; Drug Resistance, Multiple, Bacterial; Factor Analysis, Statistical; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Spain; Tazobactam | 2018 |
Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactam Resistance; beta-Lactamase Inhibitors; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Genotype; Humans; Microbial Sensitivity Tests; Molecular Diagnostic Techniques; Pseudomonas aeruginosa; Pseudomonas Infections; Sensitivity and Specificity; Tazobactam | 2019 |
Mechanisms of high-level ceftolozane/tazobactam resistance in Pseudomonas aeruginosa from a severely neutropenic patient and treatment success from synergy with tobramycin.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Bacterial; Drug Synergism; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Tobramycin; Treatment Outcome | 2019 |
Acquisition of Extended-Spectrum β-Lactamase GES-6 Leading to Resistance to Ceftolozane-Tazobactam Combination in
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Gene Expression; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2019 |
Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.
Topics: Anti-Bacterial Agents; Cephalosporins; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Queensland; Tazobactam | 2018 |
Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Bone Diseases, Infectious; Cephalosporins; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Skin Diseases, Bacterial; Tazobactam; Treatment Outcome; Urinary Tract Infections | 2019 |
Antimicrobial activity of ceftolozane-tazobactam against multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa clinical isolates from a Spanish hospital.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Colistin; Cross Infection; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Spain; Tazobactam | 2019 |
Activity of Ceftolozane/Tazobactam Against Gram-Negative Rods of the Family Enterobacteriaceae and Pseudomonas Spp. Isolated from Onco-Hematological Patients Hospitalized in a Clinical Hospital in Poland.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Enterobacteriaceae; Hospitals; Humans; Microbial Sensitivity Tests; Patients; Poland; Pseudomonas; Pseudomonas Infections; Tazobactam | 2019 |
Ceftolozane-Tazobactam Pharmacokinetics during Extracorporeal Membrane Oxygenation in a Lung Transplant Recipient.
Topics: Adult; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Extracorporeal Membrane Oxygenation; Female; Humans; Lung Transplantation; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Transplant Recipients | 2019 |
Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Biofilms; Cephalosporins; Colistin; Drug Resistance, Bacterial; Drug Therapy, Combination; Humans; Models, Theoretical; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2019 |
Successful ceftolozane-tazobactam rescue therapy in a child with endocarditis caused by multidrug-resistant Pseudomonas aeruginosa.
Topics: Cephalosporins; Child, Preschool; Endocarditis, Bacterial; Humans; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome | 2019 |
Evaluation of in vitro activity of ceftolozane-tazobactam compared to other antimicrobial agents against Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Topics: Adolescent; Adult; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Child; Child, Preschool; Cystic Fibrosis; Female; Humans; Infant; Infant, Newborn; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Young Adult | 2019 |
Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Combinations; Drug Resistance, Bacterial; Female; Hospitals; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Piperacillin, Tazobactam Drug Combination; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Scotland; Tazobactam; Whole Genome Sequencing | 2019 |
Rapidly enlarging, giant hepatic cyst growing pseudomonas.
Topics: Aged; Anti-Bacterial Agents; Cardiac Output, Low; Cysts; Drainage; Dyspnea; Female; Humans; Liver Diseases; Metronidazole; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Tomography, X-Ray Computed; Ultrasonography, Interventional | 2019 |
Prevalence of in vitro synergistic antibiotic interaction between fosfomycin and nonsusceptible antimicrobials in carbapenem-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Fosfomycin; Humans; Meropenem; Prevalence; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Tobramycin; United States | 2019 |
Impact of antibiotic resistance on outcomes of neutropenic cancer patients with
Topics: Anti-Bacterial Agents; Bacteremia; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; International Cooperation; Logistic Models; Multicenter Studies as Topic; Neoplasms; Neutropenia; Observational Studies as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Research Design; Retrospective Studies; Tazobactam; Time Factors | 2019 |
ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa.
Topics: Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2019 |
In vitro interaction of various antibiotic combinations recommended by Chinese consensus statement against carbapenems-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aztreonam; Carbapenems; Cefoperazone; Ceftazidime; China; Cross Infection; Drug Resistance, Bacterial; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2019 |
Use of continuous infusion ceftolozane-tazobactam with therapeutic drug monitoring in a patient with cystic fibrosis.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Cystic Fibrosis; Drug Administration Schedule; Drug Monitoring; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Infusions, Intravenous; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome | 2019 |
Local outbreak of extended-spectrum β-lactamase SHV2a-producing Pseudomonas aeruginosa reveals the emergence of a new specific sub-lineage of the international ST235 high-risk clone.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cephalosporins; Ciprofloxacin; Colistin; Cross Infection; Disease Outbreaks; Drug Combinations; Drug Resistance, Multiple, Bacterial; Female; France; Humans; Microbial Sensitivity Tests; Multilocus Sequence Typing; Polymorphism, Single Nucleotide; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Challenging Antimicrobial Susceptibility and Evolution of Resistance (OXA-681) during Treatment of a Long-Term Nosocomial Infection Caused by a Pseudomonas aeruginosa ST175 Clone.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Kinetics; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Whole Genome Sequencing | 2019 |
In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012.
Topics: Anti-Bacterial Agents; Canada; Ceftazidime; Cephalosporins; Cross Infection; Drug Combinations; Drug Resistance, Multiple, Bacterial; Hospitals; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2013 |
Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cephalosporins; Imipenem; Meropenem; Microbial Sensitivity Tests; Mutation; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2014 |
Role of efflux pumps: MexAB-OprM and MexXY(-OprA), AmpC cephalosporinase and OprD porin in non-metallo-β-lactamase producing Pseudomonas aeruginosa isolated from cystic fibrosis and burn patients.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactamases; Burns; Cephalosporinase; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Escherichia coli Proteins; Gene Expression Regulation, Bacterial; Humans; Membrane Transport Proteins; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2014 |
Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; Cephalosporins; Cross Infection; Enterobacteriaceae; Enterobacteriaceae Infections; Europe; Genotype; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2014 |
[Whirlpool-dermatitis with "hot hands"].
Topics: Adolescent; Drug Therapy, Combination; Hand Dermatoses; Humans; Hydrotherapy; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Water Microbiology | 2014 |
Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-Resistant Pseudomonas aeruginosa.
Topics: Aged; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome | 2015 |
In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.
Topics: Academic Medical Centers; Anti-Bacterial Agents; Cephalosporins; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Spain; Tazobactam | 2015 |
Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration.
Topics: Anti-Bacterial Agents; Cephalosporins; Critical Illness; Drug Resistance, Multiple, Bacterial; Hemofiltration; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Prospective Studies; Prosthesis-Related Infections; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2015 |
Protective effects of intravenous immunoglobulin and antimicrobial agents on acute pneumonia in leukopenic mice.
Topics: Animals; Anti-Bacterial Agents; Body Temperature; Colistin; Cytokines; Edema; Immunoglobulin G; Immunoglobulins, Intravenous; Leukopenia; Lung; Male; Mice; Mice, Inbred ICR; Penicillanic Acid; Peroxidase; Piperacillin; Pneumonia, Bacterial; Pre-Exposure Prophylaxis; Protective Agents; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2016 |
In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa in the planktonic and biofilm states.
Topics: Anti-Infective Agents, Urinary; beta-Lactamase Inhibitors; Biofilms; Cephalosporins; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2016 |
Use of Ceftolozane/Tazobactam in the Treatment of Multidrug-resistant Pseudomonas aeruginosa Bloodstream Infection in a Pediatric Leukemia Patient.
Topics: Anti-Bacterial Agents; Bacteremia; Cephalosporins; Child; Drug Resistance, Multiple, Bacterial; Hospitalization; Humans; Leukemia; Male; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2016 |
Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration.
Topics: Aged; Anti-Infective Agents, Urinary; beta-Lactamase Inhibitors; Cephalosporins; Chromatography, High Pressure Liquid; Critical Illness; Drug Resistance, Multiple, Bacterial; Hemofiltration; Humans; Male; Penicillanic Acid; Plasma; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome; United States | 2016 |
Pneumocephalus in Child Following Bilateral Otomastoiditis and Nasal Septum Infection.
Topics: Amikacin; Anti-Bacterial Agents; Humans; Infant; Male; Mastoiditis; Nasal Septum; Otitis Media; Penicillanic Acid; Piperacillin; Pneumocephalus; Pseudomonas Infections; Subdural Effusion; Tazobactam; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Humans; Male; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome | 2016 |
What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactams; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae Infections; Humans; Intraabdominal Infections; Penicillanic Acid; Pseudomonas Infections; Tazobactam; Urinary Tract Infections | 2016 |
Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; beta-Lactams; Ciprofloxacin; Cystic Fibrosis; Drug Hypersensitivity; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2016 |
Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam.
Topics: Anti-Bacterial Agents; Bacteremia; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Off-Label Use; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2017 |
Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections.
Topics: Adult; Aged; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Salvage Therapy; Shock, Septic; Survival Analysis; Tazobactam | 2017 |
Successful treatment of MDR Pseudomonas aeruginosa skin and soft-tissue infection with ceftolozane/tazobactam.
Topics: Anti-Infective Agents, Urinary; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Male; Middle Aged; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Skin Diseases, Bacterial; Soft Tissue Infections; Tazobactam | 2017 |
Evolutionary diversification of Pseudomonas aeruginosa in an artificial sputum model.
Topics: Bacteriophages; beta-Lactamases; Biodiversity; Biofilms; Biological Evolution; Culture Media; Cystic Fibrosis; Drug Resistance, Microbial; Penicillanic Acid; Phenotype; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Tazobactam | 2017 |
Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
Topics: Anti-Bacterial Agents; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Epidemiological Monitoring; Europe; Humans; Intraabdominal Infections; Israel; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Turkey; Urinary Tract Infections | 2017 |
Topics: Animals; Chemistry Techniques, Synthetic; Hydrogen-Ion Concentration; Ligands; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Quality Control; Rabbits; Radiochemistry; Radionuclide Imaging; Rats; Reducing Agents; Salmonella enterica; Salmonella Infections; Tazobactam; Technetium; Tissue Distribution | 2017 |
In vitro synergy studies based on tazobactam/piperacillin against clinical isolates of metallo-beta-lactamase-producing Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactamases; Drug Synergism; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2009 |
Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Clavulanic Acid; Gentamicins; Humans; Imipenem; Integrons; Meropenem; Molecular Sequence Data; Penicillanic Acid; Piperacillin; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections; Spain; Tazobactam; Thienamycins | 2009 |
In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Colony Count, Microbial; Disease Models, Animal; Drug Combinations; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Penicillanic Acid; Phenotype; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thigh | 2012 |
In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Enterobacteriaceae; Female; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thigh | 2013 |
Infecting one animal with two different strains of the same bacteria may cause misleading results.
Topics: Abscess; Animals; Disease Models, Animal; Enzyme Inhibitors; Hindlimb; Penicillanic Acid; Penicillins; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Reproducibility of Results; Tazobactam | 2002 |
Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis.
Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Biological Availability; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Severity of Illness Index; Tazobactam; Treatment Outcome | 2002 |
A comparison of intravitreal piperacillin/tazobactam with ceftazidime in experimental Pseudomonas aeruginosa endophthalmitis.
Topics: Animals; Anti-Bacterial Agents; Ceftazidime; Colony Count, Microbial; Drug Therapy, Combination; Endophthalmitis; Enzyme Inhibitors; Eye Infections, Bacterial; Female; Injections; Male; Penicillanic Acid; Piperacillin; Pseudomonas Infections; Rabbits; Retina; Tazobactam; Treatment Outcome; Vitreous Body | 2005 |
The efficacy of piperacillin/tazobactam in experimental Pseudomonas aeruginosa endophthalmitis: a histopathological and microbiological evaluation.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Colony Count, Microbial; Disease Models, Animal; Drug Therapy, Combination; Endophthalmitis; Eye Infections, Bacterial; Female; Male; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Tazobactam; Treatment Outcome; Vitreous Body | 2005 |
Pseudomonal sepsis with subcutaneous nodules in an HIV-infected individual with high CD4 counts.
Topics: Anti-Bacterial Agents; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4-Positive T-Lymphocytes; Gentamicins; Glucocorticoids; HIV Infections; Humans; Lymphocyte Count; Male; Middle Aged; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Pulmonary Disease, Chronic Obstructive; Respiration, Artificial; Sepsis; Skin Diseases; Tazobactam; Treatment Outcome | 2005 |
[Dynamic analysis of drug resistance of Pseudomonas aeruginosa in laboratory and clinical two-drug regimen].
Topics: Amikacin; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Sulbactam; Tazobactam | 2005 |
Piperacillin/tazobactam in treatment of brain abscess.
Topics: Anti-Bacterial Agents; Basal Ganglia; Brain Abscess; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Radiography; Tazobactam; Treatment Outcome | 2006 |
Appropriate comparators for alternate dosing strategies.
Topics: Aminoglycosides; Anti-Bacterial Agents; Cross Infection; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Male; Monte Carlo Method; Penicillanic Acid; Piperacillin; Pneumonia, Bacterial; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Risk Assessment; Tazobactam; Treatment Outcome | 2007 |
Piperacillin/tazobactam-heteroresistant Pseudomonas aeruginosa from urinary infection, successfully treated by piperacillin/tazobactam.
Topics: Adult; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Male; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Urinary Tract Infections | 2008 |
Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Chi-Square Distribution; Ciprofloxacin; Colony Count, Microbial; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Fluoroquinolones; Humans; Naphthyridines; Penicillanic Acid; Penicillins; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2000 |
Eradication of a resistant Pseudomonas aeruginosa strain after a cluster of infections in a hematology/oncology unit.
Topics: Bacteremia; Cross Infection; Drug Resistance, Multiple; Enzyme Inhibitors; Hospitals, General; Humans; Infection Control; Intensive Care Units; Microbial Sensitivity Tests; Oncology Service, Hospital; Penicillanic Acid; Penicillin Resistance; Penicillins; Piperacillin; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Sanitary Engineering; Scotland; Species Specificity; Sputum; Tazobactam | 2000 |
Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients.
Topics: Adult; Case-Control Studies; Cross Infection; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Penicillanic Acid; Penicillin Resistance; Penicillins; Piperacillin; Pseudomonas Infections; Regression Analysis; Risk Factors; Tazobactam | 2002 |